Open Orphan #ORPH – Proposed Placing to raise a minimum of £5 million to fund growth and convert hVIVO proposal pipeline
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE […]
Open Orphan #ORPH – Compulsory Acquisition of Remaining hVIVO Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY […]
Cathal Friel talks to Zak Mir about ‘sleeping giant’ hVIVO, and his plans for the new enlarged Open Orphan #ORPH
Open Orphan #ORPH announced the completion of its acquisition of UK-based hVivo Plc on Monday, 20th January 2020. Cathal Friel, Executive Chairman of Open Orphan commented, “I am hugely excited by the combination of Open Orphan and hVIVO. We have a fantastic team, substantial revenue potential and the opportunity to grow quickly in the year […]
Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. […]
Cathal Friel, Open Orphan #ORPH CEO confirms to Proactive Investors that the hVIVO deal is done
Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO to make a profit.
Open Orphan #ORPH – hVIVO merger offer now wholly unconditional
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION 17 January 2020 Recommended All Equity Offer for HVIVO PLC (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN […]
Open Orphan #ORPH – Second Closing of the hVIVO Offer, No extension of the Offer
Second Closing of the Offer No extension of the Offer Introduction On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the “Offer”). Under the terms of the Offer, hVIVO […]
Open Orphan #ORPH CEO Cathal Friel discusses contract wins & hVIVO #HVO merger on the Vox Markets podcast
Cathal Friel, CEO of Open Orphan #ORPH discusses their new 3-year contract with a tier one German pharmaceutical company and progress on their merger with Hvivo #HVO
Open Orphan #ORPH – Result of General Meeting
Open Orphan is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Company’s proposed merger with hVIVO plc and the Proposed Placing, all of the Resolutions put to the meeting were duly passed. The Board is excited by the growth potential of the Enlarged Group following completion of […]
Open Orphan #ORPH – hVIVO #HVO offer now unconditional as to acceptances
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION 31 December 2019 Recommended All Equity Offer for HVIVO PLC (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”) First Closing […]